LENZ
LENZ Therapeutics, Inc.
$10.06
+3.50%
2026-05-08
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Key Fundamentals
Forward P/E
-3.20
EPS (TTM)
$-2.85
ROE
-33.6%
Profit Margin
0.0%
Debt/Equity
0.29
Price/Book
1.07
Beta
1.67
Market Cap
$303.8M
Avg Volume (10D)
818K
Recent Breakout Signals
No recent breakout signals detected for LENZ.
Recent Price Range (60 Days)
60D High
$14.97
60D Low
$8.25
Avg Volume
886K
Latest Close
$10.06
Get breakout alerts for LENZ
Sign up for Breakout Scanner to receive daily notifications when LENZ triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
LENZ Therapeutics, Inc. (LENZ) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors LENZ daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. LENZ operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.